Fluxergy is the First Company to Utilize the National Institutes of Health Diagnostics Preclinical Services to Support Molecular Platform Development | PR Newswire [Video]

Fluxergy announces collaboration with National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID)

, /PRNewswire-PRWeb/ — FLUXERGY, an Irvine-based medical diagnostic company re-envisioning point-of-care testing with a cost-effective, all-in-one multimodal diagnostic platform, announced today that it is the first company to utilize in-kind Diagnostics Development Services from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance molecular testing and sample preparation capabilities on the Fluxergy Platform.

Under NIAID’s suite of preclinical services, NIAID-funded contractors will evaluate rapid nucleic acid extraction and purification methods compatible with the Fluxergy Test Card, with the goal of achieving high sensitivity, sample-to-answer molecular tests to be developed for gram-negative and fungal pathogens that cause sexually transmitted infections and bacterial and fungal vaginosis. These integrated extraction capabilities will be required for the development of Fluxergy’s sexually transmitted infection (STI) test and comprehensive vaginosis test.

“Fluxergy has had several successful collaborations with the …